Search Results 21-30 of 237 for USDT正规购买【电报：@xottc67788】正规平台安全有保障

  1. A Study of Standard Systemic Therapy with or without Definitive Treatment in Treating Participants with Metastatic Prostate Cancer - Mayo Clinic

    The purpose of this study is to evaouate how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) ...

  2. https://www.mayoclinic.org/arabic_patient_consumer_web.xml

  4. A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer - Mayo Clinic

    This study is to define the safety profile and to determine the maximum tolerated dose (MTD) and preliminary efficacy of AbGn-107 administered every 28 days (4 ...

  5. A Study to Evaluate the Effectiveness, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera - Mayo Clinic

    The purpose of this study is to evaluate the safety and effectiveness of idasanutlin monotherapy in participants with hydroxyurea (HU)-resistant/intolerant ...

  6. Phase 3 Study of T-DXd and Rilvegostomig versus SoC in Advanced HER2-expressing Biliary Tract Cancer - Mayo Clinic

    The purpose of this study is to to evaluate the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy vs gemcitabine, cisplatin and durvalumab as ...

  7. BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  8. PTT-936, an Alpha Kinase 1 (ALPK1) Activator, Alone or in Combination with Anti-PD-1/L1 in Patients with Locally Advanced or Metastatic Solid Tumors - Mayo Clinic

    About this study. The primary objective of this study is to evaluate the safety and tolerability of a pharmacologically active dose (PAD) range of PTT-936, ...

  9. Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy - Mayo Clinic

    Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy.

  10. Non-Hodgkin's Lymphoma Clinical Trials - Mayo Clinic Research

    Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, ...